A further analysis of clinical trial data for sipuleucel-T (Provenge) suggests that it may have delivered a greater overall survival benefit than previously described.
Anita T. Shaffer
Advertisement
Articles by Anita T. Shaffer
While oncology specialists await the latest research news from the upcoming ASCO annual meeting next month, so do legions of biopharma investors. Here's a look at companies presenting pivotol trial data at this year's conference.
Advertisement
Latest Updated Articles
Revised View Enhances Provenge OS DataPublished: April 20th 2012 | Updated:
Investors Eye ASCO Abstracts for Potential WinnersPublished: May 19th 2011 | Updated:
Advertisement
Advertisement
Trending on Medical Economics
1
The 10 places hit hardest by the government shutdown
2
As health systems grow, low-income Medicare patients lose ground, RAND study finds
3
2026 Medicare Physician Fee Schedule: Some benefits for accountable care, telehealth
4
Remote monitoring boosts Medicare revenue by 20% for primary care practices, study finds
5
